Organogenesis Holdings (ORGO) Capital Expenditures (2018 - 2026)

Organogenesis Holdings' Capital Expenditures history runs 9 years deep, the most recent figure standing at $3.1 million for Q1 2026.

• On a quarterly basis, Capital Expenditures fell 13.24% year-over-year to $3.1 million in Q1 2026; TTM through Mar 2026 was $13.7 million, a 6.21% increase from a year earlier, with the FY2025 full-year figure at $14.2 million, up 41.06% from the prior year.
• Capital Expenditures retreated to $3.1 million in Q1 2026 per ORGO's latest filing, from $4.7 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $19.2 million in Q3 2023 and bottomed at -$104000.0 in Q2 2023.
• The 5-year median for Capital Expenditures is $3.3 million (2023), against an average of $5.0 million.
• Across the five-year window, Capital Expenditures plunged 100.95% in 2023 and surged 3288.46% in 2024, its largest moves.
• Year by year, Capital Expenditures stood at $10.7 million in 2022, then plunged by 68.81% to $3.3 million in 2023, then climbed by 1.11% to $3.4 million in 2024, then soared by 38.41% to $4.7 million in 2025, then sank by 32.37% to $3.1 million in 2026.
• Per Business Quant, the three latest ORGO Capital Expenditures figures stand at $3.1 million (Q1 2026), $4.7 million (Q4 2025), and $2.2 million (Q3 2025).